Nicotine Vaccine
The Nicotine vaccine is a much anticipated stop smoking shot which holds the
promise of a quick fix to a smoker's habit. But, is it really the "Holy Grail" of smoking
cessation? The researchers at Nabi Biopharmaceuticals report some positive
results so far. Currently, the nicotine vaccine has just finished clinical phase III trials.
The nicotine vaccine works like any vaccine, by attacking the intruder entity, in this
case, nicotine. They stimulate the immune system's production of antibodies which
then attach to the nicotine molecules, making them too large to cross the
blood-brain barrier.
With the intruder effectively neutralized, the euphoric rush found with nicotine
addiction, never materializes. In addition to the primary purpose designed into the
nicotine vaccine, there is also a secondary result, which also helps the smoker lay
down those cigarettes for good. The antibodies from the nicotine vaccine stay active
in the body for the next couple of months. This latent effect helps prevent the smoker
from relapse, which is so prevalent in the first several months of cessation. This
gives the nicotine vaccine an effective 1-2 punch.
In phase I and II trials, the reported smoking cessation rates were quite favorable,
somewhere around 13-16%. Much better than most traditional stop smoking aids
currently available on the market today.
In addition, the safety profile of the nicotine vaccine seems to be very benign. There
did not appear to be any of the associated psychotic side-effects, as is found with
other stop smoking aids like Chantix or Zyban - both of which, are required by the
FDA to carry Black Box warnings.
The nicotine vaccine seemed to be a promising tool in the battle against nicotine
addiction. So, will people be lining the streets to get their stop smoking shot?
Nicotine Vaccine Update
Good question. Clinical phase III trials were completed in Nov. 2011 with
disappointing results. The nicotine vaccine (NicVAX) did not show any statistically
significant benefit over placebo. Nabi Pharmaceuticals sees this as an obvious set
back. This nicotine vaccine still has one more ongoing clinical study in the
Netherlands, but in combination with varenicline (Chantix). The results of this study
should be made available in 2012 and could determine the future of this particular
vaccine.
The Nicotine vaccine is a much anticipated stop smoking shot which holds the
promise of a quick fix to a smoker's habit. But, is it really the "Holy Grail" of smoking
cessation? The researchers at Nabi Biopharmaceuticals report some positive
results so far. Currently, the nicotine vaccine has just finished clinical phase III trials.
The nicotine vaccine works like any vaccine, by attacking the intruder entity, in this
case, nicotine. They stimulate the immune system's production of antibodies which
then attach to the nicotine molecules, making them too large to cross the
blood-brain barrier.
With the intruder effectively neutralized, the euphoric rush found with nicotine
addiction, never materializes. In addition to the primary purpose designed into the
nicotine vaccine, there is also a secondary result, which also helps the smoker lay
down those cigarettes for good. The antibodies from the nicotine vaccine stay active
in the body for the next couple of months. This latent effect helps prevent the smoker
from relapse, which is so prevalent in the first several months of cessation. This
gives the nicotine vaccine an effective 1-2 punch.
In phase I and II trials, the reported smoking cessation rates were quite favorable,
somewhere around 13-16%. Much better than most traditional stop smoking aids
currently available on the market today.
In addition, the safety profile of the nicotine vaccine seems to be very benign. There
did not appear to be any of the associated psychotic side-effects, as is found with
other stop smoking aids like Chantix or Zyban - both of which, are required by the
FDA to carry Black Box warnings.
The nicotine vaccine seemed to be a promising tool in the battle against nicotine
addiction. So, will people be lining the streets to get their stop smoking shot?
Nicotine Vaccine Update
Good question. Clinical phase III trials were completed in Nov. 2011 with
disappointing results. The nicotine vaccine (NicVAX) did not show any statistically
significant benefit over placebo. Nabi Pharmaceuticals sees this as an obvious set
back. This nicotine vaccine still has one more ongoing clinical study in the
Netherlands, but in combination with varenicline (Chantix). The results of this study
should be made available in 2012 and could determine the future of this particular
vaccine.
 | |  | |  | |  |
 | |  | |  | |  | |  | |  | |  | |  | |  | |  |
| Copyright 2010 - 2012 StopSmokingHelper.org. All rights reserved. |
Stop Smoking Help
Let us HELP you start enjoying what life can be!
| We've been helping people breathe easier for 20 years. Let our experience help you. www.stopsmokinghelper.org |
Ads
Ads
 |  |  |  |  |  |  |
